Please use this identifier to cite or link to this item:
Title: Targeting the ERBB family in cancer: couples therapy.
Austin Authors: Tebbutt, Niall C ;Pedersen, Mikkel W;Johns, Terrance G
Affiliation: Ludwig Oncology Unit, Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia
Issue Date: 16-Aug-2013
Publication information: Nature Reviews. Cancer 2013; 13(9): 663-73
Abstract: The ERBB family of receptor tyrosine kinases has a central role in the tumorigenesis of many types of solid tumour. Various therapeutics targeting these receptors have been approved for the treatment of several cancers. Considerable preclinical data have shown that the administration of two inhibitors against an individual ERBB family member--particularly epidermal growth factor receptor (EGFR) or ERBB2--leads to markedly higher antitumour activity than the administration of single agents. This Opinion article describes the preclinical and clinical performance of these dual-targeting approaches, discusses the key mechanisms that mediate their increased efficacy and highlights areas for ongoing investigation.
Gov't Doc #: 23949426
DOI: 10.1038/nrc3559
Journal: Nature reviews. Cancer
Type: Journal Article
Subjects: Antibodies, Monoclonal.administration & dosage.pharmacology
Antineoplastic Combined Chemotherapy Protocols.therapeutic use
Drug Resistance, Neoplasm
Neoplasms.drug therapy.enzymology
Protein Kinase Inhibitors.administration & dosage.pharmacology
Receptor, Epidermal Growth Factor.antagonists & inhibitors.immunology.metabolism
Receptor, ErbB-2.antagonists & inhibitors.immunology.metabolism
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Feb 25, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.